Background: Preeclampsia is a multisystmic disorder of unknown cause. Endothelial cell damage has recently been suggested to underlie the pathologic change in preeclamptic pregnancy. Thrombomodulin an endothelial cell surface glycoprotein act as a co-factor for thrombin catalyzed activation of protein C. activated protein C inhibits coagulation by inactivation the coagulation factor Va and VIIIa.
Aim of the Work: to assess the changes in thrombomodulin level in women with preeclampsia. Patients and Methods: This prospective case-control study was conducted on 123 women at Ain Shams University Maternity Hospital.
Results: Regarding clinic-pathological features of pre-eclampsia patients and healthy control groups, our study found that there was high significant difference (p≤0.01) between hypertensive and normal patients regarding (hypertension, obesity and history of PET). Our study found that there was high significant difference (p≤0.01) between pre-eclampsia patients and healthy control group regarding serum thrombomodulin protein level and serum thrombomodulin protein increases significantly with mild and severe preeclampsia and HELLP syndrome and considered a good marker for evaluation of hypertensive patients with pregnancy.
Conclusion: Serum thrombomodulin protein level is considered a good marker for evaluation of hypertensive patients with pregnancy.